These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19453402)

  • 21. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.
    Park SJ; Kim EH; Pascua PNQ; Kwon HI; Lim GJ; Decano A; Kim SM; Song MK; Shin EC; Choi YK
    J Gen Virol; 2014 Apr; 95(Pt 4):793-798. PubMed ID: 24421115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
    Hoschler K; Andrews NJ; Faust SN; Finn A; Pollard AJ; Snape MD; Walker WT; Zambon M; Miller E
    Clin Infect Dis; 2014 Jan; 58(2):181-7. PubMed ID: 24149079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
    Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
    Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
    Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season.
    Wkly Epidemiol Rec; 2011 Mar; 86(10):86-90. PubMed ID: 21395187
    [No Abstract]   [Full Text] [Related]  

  • 30. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
    Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
    Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
    Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
    Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
    Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
    Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
    Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
    Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.